*Disclaimer

AVECHO BIOTECHNOLOGY LIMITED (ASX: AVE)

🔗 📄 📈

AVE: AVE CBD capsule passes two-year stability milestone

AVECHO BIOTECHNOLOGY LIMITED

2023-06-22 08:57:00

AVE: AVE adds TPM cannabinoid gummies to portfolio

AVECHO BIOTECHNOLOGY LIMITED

2023-06-07 09:16:00

AVE: USPTO allows new TPM manufacturing patent

AVECHO BIOTECHNOLOGY LIMITED

2023-05-29 09:16:00

AVE: Avecho licenses TPM for use in cancer drugs

AVECHO BIOTECHNOLOGY LIMITED

2023-05-22 09:39:00

AVE: AVE commences manufacturing for Phase III trial

AVECHO BIOTECHNOLOGY LIMITED

2023-05-17 09:22:00

AVE: Results of Entitlement Offer

AVECHO BIOTECHNOLOGY LIMITED

2023-05-09 08:39:00

AVE: Entitlement Offer to raise $11m for Phase 3 clinical trial

AVECHO BIOTECHNOLOGY LIMITED

2023-04-03 09:40:00

AVE: Clinical CBD program expands with the Lambert Initiative

AVECHO BIOTECHNOLOGY LIMITED

2023-02-22 08:25:00

AVE: Athenex submits Avecho's phytonadione to FDA pre-IND

AVECHO BIOTECHNOLOGY LIMITED

  1. Athenex has submitted Avecho’s TPM®-enhanced phytonadione injectable product to the FDA for feedback via a pre-IND meeting request.
  2. If FDA feedback is favorable, Athenex will sign a license and development agreement with Avecho for the product and complete the remaining development work and registration for US commercialization.
  3. Athenex is a global biopharmaceutical company based in New York, US.

2023-01-12 11:49:00